HSBC Holdings
LFCR icon

HSBC Holdings’s Lifecore Biomedical LFCR Stock Holding History

HSBC Holdings’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,259
Closed -$58.4K – 2660
2023
Q1 		$58.4K Hold
15,259
– – ﹤0.01% 2556
2022
Q4 		$100K Hold
15,259
– – ﹤0.01% 2907
2022
Q3 		$138K Buy
15,259
+2,414
+19% +$24.5K ﹤0.01% 2707
2022
Q2 		$129K Sell
12,845
-2,142
-14% -$21.2K ﹤0.01% 2997
2022
Q1 		$172K Sell
14,987
-9,709
-39% -$108K ﹤0.01% 3025
2021
Q4 		$272K Buy
24,696
+11,625
+89% +$113K ﹤0.01% 2845
2021
Q3 		$121K Buy
+13,071
New +$142K ﹤0.01% 2868
2021
Q2 		– Sell
-20,132
Closed -$215K – 3010
2021
Q1 		$215K Buy
20,132
+367
+2% +$4.13K ﹤0.01% 2508
2020
Q4 		$215K Buy
+19,765
New +$204K ﹤0.01% 2774

Other funds holding LFCR

GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

HSBC Holdings's LFCR Position: Q2 2023 in Review

HSBC Holdings sold out of Lifecore Biomedical (LFCR) in Q2 2023, closing a stake of 15,259 shares — an estimated $58.4K sold.

HSBC Holdings first reported a position in LFCR in Q4 2020 and held it in 9 quarters. The position peaked at $272K in Q4 2021. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2023.

  • HSBC Holdings reported no remaining Lifecore Biomedical position as of Q2 2023 after selling out during the quarter.
  • HSBC Holdings sold 15,259 Lifecore Biomedical shares in Q2 2023, an estimated $58.4K.
  • HSBC Holdings first reported a position in Lifecore Biomedical in Q4 2020 and held it in 9 quarters.
  • HSBC Holdings's Lifecore Biomedical position peaked at $272K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2023.

Based on HSBC Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.